ReviewCurrent opinion in virology2021
Animal models of SARS-CoV-2 transmission.
Review in Current opinion in virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection.bioRxiv : the preprint server for biology · 2026Article
- Berbamine prevents SARS-CoV-2 entry and transmission.iScience · 2024Article
- Sulforaphane's Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)-Dependent and -Independent Mechanism of Anti-SARS-CoV-2 Activity.Journal of respiratory biology and translational medicine · 2024Article
- Anti-SARS-CoV-2 antibodies in a nasal spray efficiently block viral transmission between ferrets.iScience · 2024Article
- Article
- Evaluation of Binding and Neutralizing Antibodies for Inactivated SARS-CoV-2 Vaccine Immunization.Diseases (Basel, Switzerland) · 2024Article
- Bacteria Are a Major Determinant of Orsay Virus Transmission and Infection inbioRxiv : the preprint server for biology · 2024Article
- Design and validation of an exposure system for efficient inter-animal SARS-CoV-2 airborne transmission in Syrian hamsters.Microbiology spectrum · 2023Article
- Accelerating antiviral drug discovery: lessons from COVID-19.Nature reviews. Drug discovery · 2023Review
- Spread of viruses, which measures are the most apt to control COVID-19?Infectious diseases now · 2023Review
- Review
- The spike gene is a major determinant for the SARS-CoV-2 Omicron-BA.1 phenotype.Nature communications · 2022Article
- Animal models for studying coronavirus infections and developing antiviral agents and vaccines.Antiviral research · 2022Review
- SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic.Chemical biology & drug design · 2022Review
- Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.EBioMedicine · 2022Article
- Type I interferons and SARS-CoV-2: from cells to organisms.Current opinion in immunology · 2022Review
- Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.Cancer discovery · 2022Review
- Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges.PLoS pathogens · 2021Review
- SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 emerged in China as a zoonotic virus in December 2019. The virus proved to be human-to-human transmissible and its global spread resulted in the ongoing COVID-19 pandemic, associated with high morbidity and mortality. Vaccines were developed at an unprecedented speed and proved to be efficacious in preventing disease, but it remains to be determined if vaccines are able to interrupt transmission. Moreover, virus variants of concern continue to emerge that appear more transmissible and/or less sensitive to virus-specific immune responses. Here, we briefly review the role of animal models in assessing prophylactic and therapeutic options to interrupt SARS-CoV-2 transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.